Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-directed CAR-T Cell Therapy for Refractory or Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma: a Multicenter Phase I/II Trial.

NCT06101381 is registered in ClinicalTrials.gov with University of Sao Paulo as lead sponsor.

NCT NCT06101381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06101381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-directed CAR-T Cell Therapy for Refractory or Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma: a Multicenter Phase I/II Trial.
Lead sponsor
University of Sao Paulo
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 21, 2024
Completion date
December 31, 2028
Enrollment
81 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, acute lymphoblastic, lymphoma, non-hodgkin